Periodic Reporting for period 1 - APAC (Advanced Pain Control – An innovation in pain control for those suffering from secondary bone cancer)
Reporting period: 2019-07-01 to 2019-12-31
The overall objective of this project was to develop and optimize a business plan that will guide the development and commercialization of ChemoTech’s Dynamic-ElectroEnhanced Pain Control™ (D-EEPC), a revolutionary treatment for patients with bone cancer that alleviates pain through tumour bulk reduction
The feasibility study has confirmed a clear and large business opportunity within the global bone cancer treatment market and to commercialize our revolutionary medical device for pain reduction in secondary bone cancer.
We strive to validate our promising results further and validate the potential for a medical device that will improve treatment, quality of life, decrease healthcare costs and ease the financial burden posed on healthcare budgets. The problem of bone cancer is growing and ChemoTech is convinced its innovative approach will have a significant impact on the burden that bone cancer imposes in Europe and worldwide.